HEALTH: laparoscopic supracervical hysterectomy versus second-generation endometrial ablation for the treatment of heavy menstrual bleeding: study protocol for a randomised controlled trial
Authors:
- Kevin CooperKCKevin Cooper
- Kirsty McCormackKMKirsty McCormack
- Suzanne BreemanSBSuzanne Breeman
- Jessica WoodJWJessica Wood
- Neil W. ScottNSNeil W. Scott
- Jed HaweJHJed Hawe
- Robert HawthornRHRobert Hawthorn
- Kevin PhillipsKPKevin Phillips
- Angela HydeAHAngela Hyde
- Alison McDonaldAMAlison McDonald
- Mark ForrestMFMark Forrest
Open Access
- 24 January 2018
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 19 (1) , 63
Abstract
Heavy menstrual bleeding (HMB) is a common problem affecting approximately 1.5 million women in England and Wales with a major impact on their physical, emotional, social and material quality of life. It is the fourth most common reason why women attend gynaecology outpatient clinics and accounts for one-fifth of all gynaecology outpatient referrals. Initial treatment in primary care is medical - either by means of oral or injected medication or the levonorgestrel-intrauterine system (Mirena®). If medical treatment fails then surgical treatment can be offered, either endometrial ablation (EA), which destroys the lining of the cavity of the uterus (endometrium), or hysterectomy, i.e. surgical removal of the uterus. While effective, conventional hysterectomy is invasive and carries a risk of complications due to injury to other pelvic structures. The procedure can be simplified and complications minimised by undertaking a ‘supracervical’ hysterectomy where the cervix is left in situ and only the body of the uterus removed. Recent advances in endoscopic technologies have facilitated increased use of laparoscopic supracervical hysterectomy (LASH) which can be performed as a day-case procedure and is relatively easy for the surgeon to learn. HEALTH (Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding) aims to address the question ‘Is LASH superior to second generation EA for the treatment of HMB in terms of clinical and cost effectiveness?’ Women aged < 50 years, with HMB, in whom medical treatment has failed and who are eligible for EA will be considered for trial entry. We aim to recruit women from approximately 30 active secondary care centres in the UK NHS who carry out both surgical procedures. All women who consent will complete a diary of pain symptoms from day 1 to day 14 after surgery, postal questionnaires at six weeks and six months after surgery and 15 months post randomisation. Healthcare utilisation questions will also be completed at the six-week, six-month and 15-month time-points. Measuring the comparative effectiveness of LASH vs EA will provide the robust evidence required to determine whether the new technique should be adopted widely in the NHS. International Standard Randomised Controlled Trials, ISRCTN49013893 . Registered on 28 January 2014.Keywords
Funding Information
- National Institute for Health Research Health Technology Assessment Programme (12/35/23)
This publication has 16 references indexed in Scilit:
- Endometrial resection and ablation techniques for heavy menstrual bleedingCochrane Database of Systematic Reviews, 2013
- The measurement properties of the menorrhagia multi‐attribute quality‐of‐life scale: a psychometric analysisBJOG: An International Journal of Obstetrics & Gynaecology, 2011
- Thermal balloon ablation versus laparoscopic supracervical hysterectomy for the surgical treatment of heavy menstrual bleeding: A randomized studyJournal of Obstetrics and Gynaecology Research, 2011
- The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrheaArchives of Gynecology and Obstetrics, 2011
- Outcomes following hysterectomy or endometrial ablation for heavy menstrual bleeding: retrospective analysis of hospital episode statistics in ScotlandBJOG: An International Journal of Obstetrics & Gynaecology, 2011
- Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysisBMJ, 2011
- Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysisHealth Technology Assessment, 2011
- Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trialThe Lancet, 1999
- Two‐year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomesBJOG: An International Journal of Obstetrics & Gynaecology, 1999
- Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleedingBMJ, 1994